BTIG reiterates Buy on Rapport Therapeutics, lifts $75 target
BTIG maintained a Buy rating on Rapport Therapeutics with a $75.00 price target, implying 75.7% upside versus the Sep 15 close of $42.68.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.